# Shanghai Rendu Biotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shanghai-rendu-biotechnology

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.rdbio.com
- Total disclosed funding: $15M
- Latest round: Series C (Aug 13, 2018)
- Investors on record: 3

## About

Founded in 2007 and based in Shanghai, China, Shanghai Rendu Biotechnology operates as a biotechnology company that foucses on RNA molecular diagnostic technology. Chinese Journal of Antituberculosis has become the strategic partner of the company in June 2021. The company awarded as "2020 China Medical Device Technology Innovation Enterprise" in October 2021.

The company provides RNA molecular diagnostic products for many fields such as clinical testing, blood screening, food safety testing and infectious diseases. The company's develops simultaneous amplification technology and testing (SAT) technology platform and specific target capture. The company's products include reproductive health, respiratory diseases and enterovirus products. Reproductive health products include chlamydia trachomatis, neisseria gonorrhoeae and mycoplasma genitalium nucleic acid detection kit. Respiratory diseases products include novel coronavirus 2019-nCoV, universal influenza A virus and mycoplasma pneumoniae nucleic acid detection kit.

## Funding rounds

- Series C, Aug 13, 2018 — TF Capital
- Series B, Mar 10, 2016, $15M — Huagai Capital
- Series A, Dec 11, 2013 — Qiming Venture Partners

## Investors

- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series A
- Huagai Capital (https://capitalatlas.ai/funds/huagai-capital) — Series B
- TF Capital — Series C